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As regards their morphology and biology, tumours consist of heterogeneous cell populations. The cancer stem
cell (CSC) hypothesis assumes that a tumour is hierarchically organized and not all of the cells are equally capable
of generating descendants, similarly to normal tissue. The only cells being able to self-renew and produce a
heterogeneous tumour cell population are cancer stem cells. CSCs probably derive from normal stem cells, although
progenitor cells may be taken into consideration as the source of cancer stem cells. CSCs reside in the niche defined
as the microenvironment formed by stromal cells, vasculature and extracellular matrix. The CSC assays include FACS
sorting, xenotransplantation to immunodeficient mice (SCID), incubation with Hoechst 33342 dye, cell culture in
non-adherent conditions, cell culture with bromodeoxyuridine. CSCs have certain properties that make them resistant
to anticancer therapy, which suggests they may be the target for potential therapeutic strategies.
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The concept of cancer stem cells (CSCs) has attracted
researchers’ attention since the beginning of the 21st
century. It is noteworthy that this year marks the 20th
anniversary of the first experimental proof of CSCs exist-
ence [1]. Tumour cells are heterogeneous in terms of
morphology, metabolism, proliferation rate, ability to
metastasise and other features. Cancer stem cell hypoth-
esis assumes hierarchical cellular structure of a tumour,
analogous to normal tissue. The three basic functional
groups of cells are stem cells, progenitor cells and ma-
ture cells [2]. Stem cells are a minor population. They
are able to self-renew and differentiate towards mature
cells [3,4]. Stem cells rarely divide to give descendant
stem cells or progenitor cells. The latter (also known as
progenitors or transit-amplifying cells) proliferate inten-
sively. Their descendants have a more restricted poten-
tial and are able to differentiate towards a certain type of
mature cells. Progenitors have reduced capacity of self-
renewal with a limited number of divisions, in contrast
to stem cells which can divide throughout the lifespan of* Correspondence: lukasz.fulawka@gmail.com
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unless otherwise stated.the organism [4]. Mature cells are the last stage of cellu-
lar development. Having lost the ability to divide, they
contribute to the role of the tissue which they form.
Normal tissue is characterized by a fixed number of
cells. Dying mature cells are replaced by new-born ma-
ture cells derived from progenitors. This process is
strictly controlled by mutual interactions between every
cell forming the tissue. The delicate equilibrium is dis-
turbed in carcinogenesis. Cancer progenitor proliferation
gets out of control and the number of cells increases,
which is one of the tumour defining features.
The aim of this paper is to introduce and briefly de-
scribe cancer stem cell concept. We are aware of the fact
that exhaustive review of this subject is impossible
within the confines of one work. Additionally, the
current opinions about the role of CSCs in generating
tumour heterogeneity and their potential clinical impli-
cations have been presented in this paper.Historical review
The “stem cell” term was first used by a Russian re-
searcher Alexander A. Maximow as early as 1909 [5].
The era of intensive research on stem cells began in the
mid-20th century. In the 1950s Makino et al. showed in
the series of experiments that cancer cell populationl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Two features defining cancer stem cells. A – Self-renewal:
the ability to generate descendants retaining stemness characteristics.
Stem cells undergo symmetric division to give two stem cells or
asymmetric division, where one descendant remains a stem cell,
whereas the other cell loses stemness features. B - Restoration of
the heterogeneous cancer cell population. The secondary tumour is
composed of the same cell types as the primary tumour.
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subpopulation characterized by a specific karyotype. It
was proved that these cells were present in every serially
grafted derivative tumour [6,7].
In the 1960s Pierce et al. published the results of their
research, during which they isolated cells from embryonal
bodies of teratocarcinoma (the term was used to describe
a mixed type of tumour composed of teratoma and em-
bryonal carcinoma but has been largely abandoned now)
[8]. The cells were capable of differentiating into mature
tissues [2]. Later Pierce and Speers coined the hypothesis
that tumours were “caricatures” of normal tissues [2,9].
In 1961 Till and McCulloch grafted hematopoietic
cells from bone marrow of a healthy mouse into a host-
mouse whose bone marrow had been destroyed by ioniz-
ing radiation. They proved that these cells gave rise to
islets of hematopoietic stem cells in the spleen, which
differentiated towards mature blood cells [2,10,11].
Thus, the two basic features defining stem cells, namely
self-renewal and ability to differentiate into mature cells,
were revealed. In 1977 Hamburger and Salmon observed
a minor population of cells with the characteristics of
stem cells in certain types of tumours [12].
The new era of research into CSCs started in the 1990s
when their presence was proved experimentally. In 1994
Lapidot et al. reported on their breakthrough experiment.
They showed that the CD34+/CD38- cells population
(phenotype characteristic for hematopoietic stem cells) of
acute myeloid leukaemia (AML) is able to form derivative
leukaemia after transplantation into NOD/SCID (non-
obese diabetic/severe combined immunodeficient) mice
[1]. It must be also stressed that populations of a different
immunophenotype did not have this ability.
Since then serial cell transplantation into NOD/SCID
mice has been used as a gold standard in CSC research
[13], as it fulfils two crucial criteria defining CSCs - self-
renewal and ability to form heterogeneous tumour cell
population.
However, some researchers are sceptical about CSC hy-
pothesis. They claim that the results of research on NOD/
SCID mice xenotransplantation model are not sufficient
to prove the existence of CSCs. There can be other rea-
sons why a certain cell population is capable of generating
a secondary tumour after grafting, while another one is
not. The host’s microenvironment is a likely cause. In fact,
immunity in NOD/SCID mice still exists and is mediated
largely by NK cells [14,15]. Moreover, research showed
that cells of non-CSCs phenotype can form a secondary
tumour after transplantation into congenic mouse (con-
genic - differing in one locus of the genome) [16,17].
Definition of CSCs
Due to a growing interest in CSCs, a Workshop on Can-
cer Stem Cells was convened in 2006 by the AmericanAssociation for Cancer Research (AACR). The definition
of a cancer stem cell that was arrived at in the Work-
shop has been generally used since that time. CSC was
defined as “a cell within a tumour that possesses the
capacity to self-renew and to cause the heterogeneous
lineages of cancer cells that comprise the tumour” [13].
What does the term “self-renewal” mean? Every tissue is
a dynamic structure composed of cells characterized by a
given lifespan which is generally much shorter than the
lifespan of the whole organism. In this respect brand new
cells need to be produced to substitute for the dying ones.
They are generated from resting cells (i.e. cells with low
biochemical activity and rarely dividing) defined as stem
cells [2]. Their number needs to be constant to maintain
the tissue alive. To achieve this goal, at least one cell needs
to be a copy of its mother cell (Figure 1A). When the
other cell is directed into a differentiation program, the
division is defined as asymmetric [2,7,18]. The other
mechanism of stem cells division produces two identical
stem cells and is referred to as a symmetric cell division.
Therefore self-renewal is defined as the ability to generate
descendants retaining stemness characteristics [7].
The ability to produce a heterogeneous cell population
is linked to cells isolated from a tumour (Figure 1B). To
show this feature the experimental model should be used.
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munosuppressed organism whose immune system does
not reject grafted cells. The above mentioned NOD/SCID
mouse model is generally accepted in this issue [13]. The
ability to generate a heterogeneous secondary tumour cell
population, which is identical to the primary tumour, de-
notes that there were CSCs amongst transplanted cells.
The term “tumour-initiating cell” or “tumorigenic cell” are
often used to emphasize this feature and thus can be
treated as the synonyms for CSC. However, these terms
can lead to a confusion with the first cell that was initiated
and gave rise to cancer in the patient [13,19]. For that rea-
son some authors avoid using these phrases and propose
the term “tumour-propagating cells” (TPCs) [19].
Tumour heterogeneity
Morphological diversity of cells, as seen under a micro-
scope, is much more pronounced in the tumour com-
pared to normal tissue. It is one of the features of
atypia, the term used to define malignancy in histopath-
ology. There are also differences amongst tumour cells
in a phenotype (for instance: expression of surface anti-
gens and cytoplasmic proteins, activity of biochemical
processes) and functionality (for instance: proliferation
rate, invasion, metastases forming, activation of neoangio-
genesis, resistance to systemic therapy) [3,20]. The key fac-
tors responsible for tumour heterogeneity are genomic
heterogeneity, hierarchical organization of tumour tissue,
environmental influences and random processes [21,22].Figure 2 Basic tumour heterogeneity models. A - Clonal evolution mod
of cells differing in genotype and thus phenotype. The best fitted cells are
tumour. B - Cancer stem cell model. CSC population is capable of unlimite
phenotypically diverse populations of different stages of cell maturation.Genomic heterogeneity results from genomic instabil-
ity and increased proliferation rate [20,21]. Mutated cells
undergo natural selection in the Darwinian evolution
mechanisms (Figure 2A) which favour better adjusted
cells. These cells live longer and give rise to descendant
cells. The clones are generated as tumour grows. Thus
tumour mass is heterogeneous as it consists of clonal
variants [21,22].
The cancer stem cell model assumes that tumour tissue
is hierarchically organized. CSCs population is responsible
for tumour growth and progression (Figure 2B). In this re-
spect heterogeneity means presence of cells at different
stages of maturation [21].
Clonal evolution and CSC models describe the basic
mechanisms leading to tumour heterogeneity [21]. Gen-
omic heterogeneity has been proved by genomic re-
search results [23]. The question that remains is whether
most of tumour cells or only CSCs undergo clonal evo-
lution. It is possible that only a minority of tumours are
hierarchically organized and clonal evolution of CSCs
occurs only in these cases [24] (Figure 3).
Like normal tissue, tumour cells are prone to influences
from the microenvironment (stromal cells, extracellular
matrix). The difference is that tumour tissue is character-
ized by a profound disarrangement of microenvironment.
A wide variety of microenvironmental influences contrib-
utes to tumour cell heterogeneity [21]. The random (sto-
chastic) processes result from random biochemical
reactions. There is also another phenomenon referred toel. High proliferation and genomic instability result in a large number
selected by Darwinian processes to generate clonal variants of the
d number of divisions. Tumour heterogeneity results from existence of
Figure 3 Clonal evolution and CSCs model are not exclusive.
The population of CSCs may undergo clonal evolution. Tumour
heterogeneity results from existence of both clonal variants and
different stages of cell maturation.
Figure 4 The historical concepts of CSCs origin. A - Embryonal
rest theory. The pluripotent embryonal cells remain in the adult or-
ganism in the form of “embryonal rest”. They are the origin of CSCs.
B - Dedifferentiation theory. Somatic stem cells of adult tissue gain
pluripotency through dedifferentiation.
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of transcription between cells [21].
The sources of CSCs
The concept of CSCs has been discussed in the scientific
literature since the 19th century. In 1874 Durante hypothe-
sised that tumours derive from a rare cell population of
stem cell characteristics [7]. Simultaneously, Conheim
(Virchow’s student) speculated that these cells may be em-
bryonal cells, which remain in the adult organism, retain-
ing their pluripotency (Figure 4A). This concept was
called the “embryonal rest theory” [2,7]. In the late 19th
century this hypothesis was gradually replaced by dediffer-
entiation theory of carcinogenesis (Figure 4B). It assumed
that adult differentiated cells are the source of cancer stem
cells after process of dedifferentiation, i.e. reversal of dif-
ferentiation [2]. In the mid-20th century, when stem cells
were gaining more attention, the concept binding together
tumours and stem cells became attractive again.
It is a common mistake to treat a CSC as a synonym of
a normal stem cell which has gone through carcinogenesis
to initiate tumour [13,24]. In this regard, some authors
prefer using the term “tumour-initiating cells” [25]. To de-
scribe the former entity, the term “cancerous stem cell”can be used [26]. There are discrepancies between investi-
gators regarding the source of CSCs. Intuitively, normal
stem cells are likely to be the target of oncogenic initiation
leading to the formation of CSCs [13,26].
Similarly to normal tissue, CSCs give rise to progenitor
cells which are an intensively proliferating cell popula-
tion. Normal progenitors differentiate after a certain
numbers of divisions and lose their ability to divide (ter-
minal differentiation). However, cancer progenitor cells’
ability to proliferate is much higher. Thus, their progeny
is much more numerous and accumulates, which leads
to an increase in tumour mass [2].
CSCs may also derive from normal progenitor cells
which acquired self-renewal ability in the course of accu-
mulating mutations during carcinogenesis [13,25]. Some
experiments seem to confirm this hypothesis. In one of
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transplantation of hematopoietic progenitor cells with
transduced MLL oncogene [18,27]. The results of the
last research revealed unexpectedly that CSCs may de-
rive from differentiated epithelial cells in the process of
epithelial-mesenchymal transition (EMT) [28,29].
Epithelial-mesenchymal transition and metastases
Epithelial-mesenchymal transition is a process occuring dur-
ing development of multicellular organisms. The epithelial
cells acquire mesenchymal properties by loss of cell-cell
junctions and polarity [29]. Owing to migratory and invasive
capabilities, mesenchymal cells are concordant with cancer
phenotype. Thus it has been proposed that EMT contribute
to cancer development. The results of recent studies suggest
that EMT produces cells with CSCs features in breast, pan-
creatic and colorectal cancers [30].
The metastasis process begins with detachment of cells
from primary tumour and migration into the lumen of
blood or lymphatic vessels (intravasation). The cells gain
these features during EMT. The concept that CSCs may
be metastatic precursor is supported by the fact that ex-
pression of CSCs markers by tumour seems to predict
metastases [25]. The crosstalk between CSCs and EMT
is also confirmed by the coexpression of stemness and
mesenchymal-like profile in epithelial tumours [28]. The
Wnt pathway seems to be the clearest molecular con-
nection between EMT and stemness [28].
CSC niche
Stem cells reside in the niche which is defined as a
microenvironment made up of adjacent stromal cells,
vessels and extracellular matrix [18]. The cells are sus-
tained in undifferentiated state by the niche, which pro-
tects them from factors stimulating differentiation. The
other way to sustain stemness by the niche is to limit
the proliferation rate of stem cells [13,31]. The elements
forming the niche adhere to stem cells with adhesion
molecules and control their function by signalling mole-
cules, such as Shh (Sonic hedgehog), BMPs (bone mor-
phogenic proteins) and Notch [32]. The constant
number of stem cells may be also maintained by limited
physical space of the niche. If cell division occurs in the
“completely occupied” niche, one of the descendant cells
must leave the niche. It then begins to differentiate be-
cause it is not exposed to niche factors maintaining
stemness. This process is called asymmetric cell division
[31,32] that was referred to above. On the contrary, if
there is free space in the niche, two descendant cells stay
in it and are sustained in stemness [31]. This phenomenon
is referred to as a symmetric cell division.
CSCs, similarly to their healthy counterparts, retain
their self-renewal ability by interaction with the niche
[13]. As the tumour grows, the number of niche cellsprobably increases. This phenomenon may be due to
the stimulation of the niche cells to proliferate by CSCs
[33]. Niche elements may be also transformed to lose
their ability to control proliferation of themselves and
of stem cells [33]. The transformation may also modify
the niche cells to produce stimulating proliferation fac-
tors [13]. It may drive clonal selection of mutated stem
cells and transform them into CSCs. It is also possible
that stem cells gain independence from factors sup-
pressing their proliferation (including the niche) or get
the ability to occupy other niches on their way through
carcinogenesis [13,33].
Methods of detection and isolation of CSCs
According to the definition coined by AACR Workshop
on Cancer Stem Cells, tumour cell population could be
defined as CSCs if it is experimentally showed to produce
a secondary tumour which is composed of identical het-
erogeneous cell population as the primary tumour [13].
To prove it, the cell population which is examined, needs
to be isolated from other cells forming the tumour. A
specialized type of flow cytometry, FACS (fluorescence-
activated cell sorting) is used (Figure 5) for that purpose. If
a solid tumour is examined, it is exposed to enzymes that
degrade intercellular junctions and bounds between the
cells and extracellular matrix. Then, the cell suspension
flows through a narrow tunnel to form a single-cell stream.
It is directed into a vibrating nozzle which breaks it apart
into droplets containing single cells [34]. Every droplet
goes through a laser beam. Cells differ in their optical char-
acteristics, i.e. rate of absorption, emission and dispersion.
These features are caught by detectors. Then, cells of cer-
tain characteristics are charged electrostatically and they
are directed to electrostatic field. The phenomenon of elec-
trostatic deflection bends the charged cell flow. The cells
are collected in the vessel [34]. The remaining electrostati-
cally uncharged cells flow vertically down.
FACS can be used to isolate cells differing in surface
markers phenotype [34]. In this case, cell suspension is
incubated with an antibody specific for a certain surface
antigen, conjugated to fluorescent dye. Then cells flow
through a laser light beam of wavelength adjusted to a
fluorescent dye used. Opsonized (thus expressing certain
antigen) cells are isolated using electrostatic deflection
described above.
Alternatively, antibody bound to magnetic beads can
be used. In this method, called magnetic-activated cell
sorting (MACS), the cell suspension stream into a strong
magnetic field. The cells expressing marker specific to
the antibody used, stay in the magnetic column, while
other cells flow through. Later, the column is removed
from the magnetic field and the remaining cells are
washed out.
Figure 5 The stages of CSCs isolation by FACS. A - Solid tumour is digested by enzymes to cell suspension. B - Tumour cell suspension is
incubated with antibodies directed against antigens specific for CSCs conjugated with fluorescent dye. C - The opsonized cell suspension is let
through a narrow tunnel to form a single-cell-diameter stream. The vibration produces droplets containing single cells at the mouth of the tunnel.
D - The droplets pass through a laser beam. The fluorescent dye is excited to emit the light identified by a detector. E - The detector is paired
with the device which gives electrostatic charge to light-emitting cells. The “dark” cells remain uncharged. F - The flow of electrostatically charged
cells is bent by the electric field. The cells are collected in the tube. The uncharged cells fall by gravitation.
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actively move xenobiotics out of them. It is defined as
efflux. It results from increased expression of membrane
proteins of ABC family. These proteins are responsible for
Hoechst 33342 dye efflux [7,35]. Cell suspension is incu-
bated with Hoechst 33342 and then FACS sorting is used.
The dye-negative fraction is called side population (SP)
[7,36]. However, it is generally assumed that SP population
is not synonymous with CSCs. Some researchers hypothe-
sise that it may even not contain CSCs [13].
The gold standard in CSC research, as mentioned above,
is xenotransplantation into immunodeficient animals. To
examine if a certain cell population contains CSCs using
this method, the candidate cells need to be isolated first.
FACS sorting is used for this purpose. Then, isolated cells
are injected subcutaneously or intraperitoneally into mice
(Figure 6). When a secondary tumour is formed in a hostorganism, the procedure of isolation and transplantation is
repeated. If it gives rise to a tertiary tumour consisting of
identical heterogeneous cell population as the primary
tumour, it is highly probable that the examined cells are
CSCs [13].
Another method to detect CSCs is adhesion free cell
culture. Every cell remains in suspension for its entire
lifespan. If a certain cell gives rise to the population of
progeny, they stay bound together in the form of a free
floating colony of spheroid shape [7].
CSCs, similarly to normal stem cells, proliferate
rarely. This feature is detected by label retention assay
[13]. The most commonly used one is bromodeoxyuri-
dine (BrdU). This nucleotide is incorporated into the
DNA. The more cell divisions occur, the more diluted
BrdU becomes. Thus CSCs retain more BrdU than
other cells.
Figure 6 CSCs xenotransplantation into SCID mouse. A - Cell suspension containing FACS-isolated CSCs is injected subcutaneously or
intraperitoneally into SCID mouse. B - Generation of a secondary tumour with heterogeneous population, analogous to the primary tumour, is
highly conclusive of CSCs existence in cell suspension.
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There are no universal markers of CSCs. In addition, no
potential marker is uniquely specific for stem cells. It is
a common mistake to assume that the phenotype of
CSCs of a certain tumour could be identical or even
similar in the other type of tumour [13]. Amongst many
potential markers of CSCs, two most numerous groups
can be highlighted, i.e. membrane antigens and tran-
scription factors. Only well-established markers are dis-
cussed here since we assumed that it was impossible to
describe all of the potential CSCs markers in this paper.
The first malignancy proved to contain CSCs was
acute myeloid leukaemia. It was shown that leukemic
stem cells possess CD34+CD38- phenotype [1]. Breast
cancer was the first solid tumour that CSCs were iso-
lated from. It was proved that a relevantly lower number
of CD44+/CD24- cells was able to initiate a secondary
tumour after grafting into NOD/SCID mouse than any
other phenotype [37]. The expression of CD44 antigen
was then revealed in cells initiating prostate cancer [38],
pancreatic cancer [39] and head and neck squamous cell
carcinoma [40]. The other surface antigen, CD133, was
proved to be a marker for stem cells of brain tumours
[41], colorectal cancer [42,43] and lung cancer [44].
CD90+/CD45- phenotype was revealed in CSCs of hepa-
tocellular carcinoma [45]. For practical purposes, surface
markers are the most useful, due to the fact that they
allow the isolation of intact cells.
In 2006 Takahashi and Yamanaka described their experi-
ment during which different transcription factors were in-
troduced into mouse fibroblasts [46]. They proved that
only four of them (Oct4, Sox2, c-Myc and Klf4) were suffi-
cient to gain pluripotency (ability to differentiate into
every tissue of the organism). These cells were named in-
duced pluripotent stem cells (iPSCs) and the four factors
were later called Yamanaka’s factors [8]. Soon after that Yu
et al. generated iPSCs from human somatic cells [47]. In
this case only three factors (Oct4, Sox2 and Nanog) were
sufficient to create iPSCs. The expression of these factors
was revealed in prostate cancer stem cells [48]. Oct4
marker was also proved to be CSCs marker of breast [49]
and urinary bladder cancer [50]. For the abovementionedreason, the transcription factors are less useful in func-
tional testing than surface markers.
ALDH (aldehyde dehydrogenase) is considered to be
yet another important marker of CSCs [7]. Breast cancer
was the first tumour whose stem cells were showed to
have increased ALDH1 isoform activity [51]. The ele-
vated activity of this enzyme was also revealed in acute
myeloid leukaemia [52], prostate cancer [53] and hepato-
cellular carcinoma [54].
It is worth to mention that a subset of cells isolated on
the basis of certain markers expression is not equivalent
of CSCs population. If it were true, every single isolated
cell would be capable of spheroid formation or gener-
ation of secondary tumour after xenotransplantation. As
we know, more than one cell is needed to accomplish it.
Moreover, the definition of CSCs in some tumours has
been narrowed after additional research. The further re-
finements of CSCs phenotypes are expected, as it hap-
pened recently in the case of breast cancer. In this
example, the initial definition of CD44highCD24low cells
was narrowed to a subset additionally expressing gan-
glioside GD2 [55].
Furthermore, distinct subsets within the same tumor
entity can show stemness characteristics. A good ex-
ample is glioblastoma, where both CD133+ and CD133-
subtypes were similarly tumorigenic in nude mice
in vivo [56]. It was shown that these subsets were char-
acteristic for different tumour subtypes (mesenchymal
and pro-neural) - which had not been appreciated on
histological examination [56]. In this respect, we cannot
expect clearly defined CSCs markers to be specific for
certain tumour entity. On the other hand, expression of
CSCs markers can enable to divide certain diagnostic
entity into prognostic group. For example, research re-
vealed that CD133 expression in oligodendroglial tumors
indicated shorter survival and predicted poorer clinical
outcome [57].
The role of CSCs in anticancer therapy
Classical anticancer strategies (chemotherapy and radio-
therapy) kill intensively proliferating cells, which leads to
cytoreduction and regression of malignant lesion. The
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source of every cancer cell. They are a rarely dividing
population, so anticancer agents may not eradicate them,
which may lead to the development of minimal residual
disease (MRD), which in turn may be the cause of recur-
rence [14,18,58].
Moreover, CSCs have inherited or acquired resistance
to anticancer therapy. The reasons for that may be ele-
vated activity of mechanisms of DNA damage detection
and repair, aberrations in apoptotic pathways, increased
ability of xenobiotic efflux, reduced production of free
radicals or elevated production of certain interleukins
[14,58,59].
Efficient anticancer therapy should eliminate cancer
stem cells as the potential source of recurrence. In this
respect, CSCs are a promising target for potential thera-
peutic strategies. It must be emphasised that drugs must
be as specific as possible towards CSCs to spare healthy
stem cells.
There are a few potential therapeutic strategies against
CSCs: direct killing by a chemotherapeutic agent bound
to an antibody specific for membrane antigen, suppres-
sion of self-renewal pathways, blocking of therapy-
resistance mechanisms and induction of differentiation
[14]. However, it is yet too early to say if all or any of
these methods would result in victory in the battle
against cancer.
Conclusions
The concept of crosstalk between stem cells and cancer
appeared as early as in the 19th century. The existence
of CSCs was experimentally proved in 1990s. Currently,
the cancer stem cells hypothesis assumes hierarchical
cellular structure of a tumour, with CSCs population
capable of self-renewal and production of a heteroge-
neous tumour cell population. The number of potential
CSCs markers have been recently reported. The ongoing
research reveals the possible role of CSCs markers as a
prognostic factors in cancer diagnostics. Moreover, they
can act as the target for future anticancer therapy.
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